Intrahepatic interferon-stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?

Hepatology

Volumn 46, Issue 5, 2007, Pages 1326-1328

  Shackel, Nicholas A ^b   McCaughan, Geoffrey W ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYXOVIRUS RESISTANCE PROTEIN A;

ADAPTIVE IMMUNITY; EDITORIAL; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; GENE; INTERFERON STIMULATED GENE; LIVER BIOPSY; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 36348988969     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22006     Document Type: Editorial

References (20)

1. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-952.
2. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444.
3. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006;131:1584-1591.
4. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007;81:3391-3401.
5. Feld J, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment responses. HEPATOLOGY 2007;46. DOI 10.1002/hep.21853.
6. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006;16:141-147.
7. Takehara T, Hayashi N. Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity. Clin Gastroenterol Hepatol 2005;3:S78-S81.
8. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003;74:360-369.
9. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. HEPATOLOGY 2006; 44:1617-1625.
10. MacQuillan GC, de Boer WB, Platten MA, McCaul KA, Reed WD, Jeffrey GP, et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol 2002;68:197-205.
11. Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002;76:8189-8199.
12. Johnson CL, Owen DM, Gale M Jr. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 2007;282:10792-10803.
13. Nakano I, Fukuda Y, Katano Y, Toyoda H, Hayashi K, Hayakawa T, et al. Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut 2001;49:263-267.
14. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323.
15. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, et al. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype lb chronic hepatitis C. J Gen Virol 2005;86:1067-1075.
16. Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, et al. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol 2003;39:421-427.
17. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779-13792.
18. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75:7059-7066.
19. He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. HEPATOLOGY 2006;44:352-359.
20. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus. HEPATOLOGY 2007;46:999-1008.